Australia’s CSL delays spinoff as US flu vaccination rates decline
By Rishav Chatterjee (Reuters) – Australian biotech CSL on Tuesday delayed the planned spin-off of its vaccines division and cut its profit forecast due to a bigger-than-expected drop in flu vaccination rates in the United States, sending its shares down as much as 16.6%. The company told shareholders in August it would spin off CSL…